"Brazil Pharmaceuticals & Healthcare Report Q2 2011" now available at Fast Market Research

April 24, 2011 - PRLog -- BMI View: Brazil is Latin America's most attractive emerging pharmaceutical market. Driven by a booming economy and underpinned by political stability, demand for medicines, both generic and patented, will continue to increase. Indicating a long-term commitment to the region, pharmaceutical companies are increasingly investing in manufacturing facilities and, to a lesser extent, research and development (R&D) plants. Competition in the domestic arena is set to intensify due to Brazil's current industrial policy, which has a strong focus on developing domestically owned pharmaceutical manufacturers in the private sector. However, BMI's prediction that pharmaceutical sales growth will decrease slightly in 2011 due to inflationary pressures, leading to higher drug prices and decreased access to credit, resulting in lower levels of consumer spending, is looking increasingly likely.

Headline Expenditure Projections

* Pharmaceuticals: BRL36.9bn (US$20.8bn) in 2010 to BRL39.63bn (US$22.8bn) in 2011; +7.5% in local currency terms and +9.7% in US dollar terms. Forecast down moderately from Q111 due to macroeconomic factors.
 * Healthcare: BRL300.8bn (US$169.9bn) in 2010 to BRL332.0bn (US$191.4bn) in 2011; +10.4% in local currency terms and +12.6% in US dollar terms. Forecast unchanged from Q111.
 * Medical devices: BRL6.6bn (US$3.76bn) in 2010 to BRL7.36bn (US$4.24bn) in 2011; +10.6% in local currency terms and +12.8% in US dollar terms. Forecast unchanged from Q111.


Business Environment Rating

BMI's average Business Environment Rating for the 17 Americas markets has moved down from 49.0 to 48.8. Brazil maintained a composite pharmaceutical rating of 63.3, remaining fourth in the Americas rank matrix. On a global basis, Brazil has risen through the ranks to 15th position, overtaking China, which previously had equal score but has now dropped to 17th position among the top-scoring emerging markets. As a region, the Americas rank second only behind Western Europe in terms of attractiveness to multinational drugmakers.

BMI Economic View: Local reports that the finance ministry is planning to reclassify some of 2010's PAC expenditure in a bid to meet the government's primary fiscal surplus target reinforces our view that Brazil's public accounting methodologies are becoming increasingly opaque. With the government having already reduced its primary surplus target to 3.1% of GDP for 2010 and 2011 (down from 3.3% previously), and removed several key state companies from its primary surplus calculations, the move is likely to exacerbate investor fears that the authorities are redrawing the fiscal accounts to give a healthier picture of the country's public finances.

BMI Political View: New President Dilma Rousseff faces a testing start to the year, with key challenges building up that will influence governability during the first part of her term. Of particular importance will be elections for the presidencies of the two houses of congress, where victories for the leading members of the ruling bloc would help to speed up the progress of legislation. Moreover, a positive outcome would strengthen the executive's bid to cap the annual minimum wage increase in the face of major objections from the country's powerful labour unions.

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/149593_brazil_pharmaceuticals_...


Partial Table of Contents:

SWOT Analysis
- Brazil Pharmaceuticals And Healthcare Industry SWOT
- Brazil Political SWOT
- Brazil Economic SWOT
- Brazil Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Americas Pharmaceutical Business Environment Ratings, Q211
- Rewards
Brazil - Market Summary
Regulatory Regime
- Intellectual Property Environment
- Counterfeits
- Regulator Interference
- Compulsory Licensing
- Pricing and Reimbursement Issues
- Tax Burden on Pharmaceuticals
- OTC Regulations
- Advertising
- Other Regulatory Developments
Industry Developments
- Epidemiology
- Healthcare Sector
- PROFARMA Initiative
- Research and Development
- Clinical Trials
Industry Forecast Scenario
- Overall Market Forecast
- Table: Pharmaceutical Sales Indicators 2007-2015
- Key Growth Factors - Industry
- Table: Healthcare Expenditure Indicators 2007-2015
- Table: Government Healthcare Expenditure Indicators 2007-2015
- Table: Private Healthcare Expenditure Indicators 2007-2015
- Key Growth Factors - Macroeconomic
- Table: Brazil - Economic Activity
- Prescription Drug Market Forecast
- Table: Prescription Drug Sales Indicators 2007-2015
- Patented Drug Market Forecast
- Table: Patented Drug Market Indicators 2007-2015
- Generic Drug Market Forecast
- Table: Generic Drug Sales Indicators 2007-2015
- OTC Medicine Market Forecast
- Table: OTC Medicine Sales Indicators 2007-2015
- Pharmaceutical Trade Forecast
- Table: Exports and Imports Indicators 2007-2015
- Medical Device Market Forecast
- Table: Medical Devices Sales Indicators 2007-2015
- Key Risks to BMI's Forecast Scenario
Competitive Landscape
- Top 20 Pharmaceutical And Healthcare Companies In Brazil By Revenues 2009
- Innovative Drugmakers
- Innovative Drugmakers - Quarterly Developments
- Generic Drugmakers
- Generic Drugmakers - Quarterly Developments
- OTC Sector
- Distribution Sector
- Retail Market - Recent Developments
Company Monitor
- Ache/Biosintetica
- EMS Sigma
- Eurofarma
- Medley
- Cristalia
- Sanofi-Aventis
- Pfizer
- Merck and Co
- Novartis
- GlaxoSmithKline (GSK)
- Roche

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=1495...

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.